Holen Sie sich die Stockscreener-App
7.56
1.31%
-0.10
Schlusskurs vom Vortag:
$7.66
Offen:
$7.65
24-Stunden-Volumen:
877.84K
Relative Volume:
23.24
Marktkapitalisierung:
$1.61B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-7.9287
EPS:
-0.9535
Netto-Cashflow:
-
1W Leistung:
+3,586%
1M Leistung:
+3,586%
6M Leistung:
+3,586%
1J Leistung:
+3,586%
1-Tages-Spanne:
$7.54
$7.80
1-Wochen-Bereich:
$7.54
$8.1199
52-Wochen-Spanne:
$7.54
$8.1199
Blackrock Technology And Private Equity Term Trust Stock (BTX) Company Profile
Firmenname
Blackrock Technology And Private Equity Term Trust
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BTX
Blackrock Technology And Private Equity Term Trust
|
7.56 | 1.61B | 0 | 0 | 0 | 0.00 |
|
DNP
Dnp Select Income Fund Inc
|
9.45 | 3.50B | 0 | 0 | 0 | 0.00 |
|
UTG
Reaves Utility Income Fund
|
33.40 | 2.94B | 0 | 0 | 0 | 0.00 |
|
ETY
Eaton Vance Tax Managed Diversified Equity Income Fund
|
15.27 | 2.40B | 0 | 0 | 0 | 0.00 |
|
ADX
Adams Diversified Equity Fund
|
20.36 | 2.39B | 0 | 0 | 0 | 0.00 |
|
UTF
Cohen Steers Infrastructure Fund Inc
|
24.54 | 2.37B | 0 | 0 | 0 | 0.00 |
Blackrock Technology And Private Equity Term Trust Stock (BTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-10-06 | Eingeleitet | Maxim Group | Buy |
Blackrock Technology And Private Equity Term Trust Aktie (BTX) Neueste Nachrichten
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - Defense World
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eterna Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Eterna Therapeutics faces Nasdaq delisting over share price - Investing.com India
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - Defense World
BNY Mellon Ultra Short Income ETF (NYSEARCA:BKUI) Stock Price Up 0% – Should You Buy? - Defense World
Athersys (NASDAQ:ATHX) Research Coverage Started at StockNews.com - Defense World
StockNews.com Begins Coverage on Avangrid (NYSE:AGR) - Defense World
General Electric (NYSE:GE) Shares Bought by Creative Planning - Defense World
Week Ahead (Apr.12- Apr.16): PDUFA Dates, Data Readouts (RCUS, ATXI, MRTX, KDNY…) - RTTNews
‘Today you’re going to die’. Man ‘disrespected’ at family event kills cousin, MN cops say - Kansas City Star
15-Year-Old Shot Outside Brooklyn High School: Police - Patch
Teen Shot Outside Brooklyn High School - BK Reader
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $87.23 Million Holdings in Intuit Inc. (NASDAQ:INTU) - MarketBeat
Eterna Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Eterna Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Itau Unibanco Holding S.A. Takes Position in Bristol-Myers Squibb (NYSE:BMY) - Defense World
Video NYPD releases body camera video of police shooting at Brooklyn Subway station - ABC News
Brooklyn Farebeater Who Cops Shot Pleads Not Guilty From Hospital Bed - Brooklyn, NY Patch
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com - MarketBeat
Eterna Therapeutics sets September 27 for annual meeting - Investing.com
Exclusive: RNA firm Eterna Therapeutics buys neighboring startup for $50M - The Business Journals
Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights - GlobeNewswire
Kevin D’Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer - Business Wire
ERNA Stock Price and Chart — NASDAQ:ERNA - TradingView
Eterna Therapeutics Completes Name Change, Acquires Option - GlobeNewswire
Brooklyn hails immunotherapy for achieving 'primary objective'—but fails the primary endpoint - Fierce Biotech
“Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy” published in Chemical Reviews, selected as VINSE Spotlight Publication - Vanderbilt University
SpyBiotech Appoints Mark Leuchtenberger as Chief Executive Officer - citybiz
iPSC-derived dopamine progenitor cell therapy in Parkinson’s disease - RegMedNet
Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement - StockTitan
Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index - StockTitan
Longeveron: A Meme Stock That Will Oscillate Before Dropping (NASDAQ:LGVN) - Seeking Alpha
New R&D Center Will Focus on Cell-based Therapies - Sickle Cell Disease News
7 Top-Rated Pharmaceutical Companies to Invest In for July - InvestorPlace
Swedish MPA Approves Atossa Therapeutics Inc (NASDAQ: ATOS) To Conduct Phase 2 Clinical Trial Of Oral Endoxifen To Reduce Mammographic Breast Density - BP Journal
10 Top Penny Stocks On Robinhood To Watch Right Now Before July 2021 - Penny Stocks
Brooklyn Immunotherapeutics Inc (NYSEAMERICAN: BTX) Incorporates R&D Center In Cambridge, Massachusetts To Develop mRNA-based Gene Editing/ Cellular Therapies - BP Journal
Brooklyn ImmunoTherapeutics Stock Rises After Novellus Therapeutics Buyout Deal - Benzinga
Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company’s Future During May 25, 2021 Shareholder Update Call - StockTitan
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing - Business Wire
Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc. - Business Wire
CDE China Grants IND Approval For Vicineum Of Sesen Bio Inc (NASDAQ:SESN) - BP Journal
Christopher Rohde, Ph.D. to Join Scientific Advisory Board of Brooklyn ImmunoTherapeutics - citybiz
Citius Pharmaceuticals Inc (NASDAQ:CTXR) Reports Strong Presence Of Clinical Trial Staff, Investigators, And Referring Physicians In A Webinar On Mino-Lok Phase 3 Clinical Trial - BP Journal
Brooklyn ImmunoTherapeutics: Time To Sell (NYSE:BTX) - Seeking Alpha
Erich Mohr, Ph.D., to Join the Board of Directors of Brooklyn ImmunoTherapeutics - citybiz
Finanzdaten der Blackrock Technology And Private Equity Term Trust-Aktie (BTX)
Es liegen keine Finanzdaten für Blackrock Technology And Private Equity Term Trust (BTX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.89%
Kapitalisierung:
|
Volumen (24h):